Quantum BioPharma seeks shareholder approval for $600 private placement

Quantum BioPharma Ltd. (NASDAQ: QNTM) will seek shareholder approval for a non-brokered private placement of class A multiple voting shares for aggregate gross proceeds of up to $600 at its annual general and special meeting on September 26, 2025.

The biopharmaceutical company expects existing holders of multiple voting shares to subscribe for the entirety of the offering. The transaction is expected to close on or about September 26, 2025, subject to receiving requisite shareholder approval at the meeting.

All securities issued pursuant to the offering are subject to a statutory hold period of four months plus a day from issuance in accordance with applicable Canadian securities laws. The company intends to use proceeds for general working capital purposes.

Quantum BioPharma filed a material change report more than 21 days before the expected closing of the offering in accordance with Multilateral Instrument 61-101 on its SEDAR+ profile. The company initially announced the private placement on June 27, 2025.

The company operates as a biopharmaceutical firm focused on building a portfolio of assets and biotech solutions for neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., Quantum BioPharma develops Lucid-MS, described as a patented compound shown to prevent and reverse myelin degradation in preclinical models.

The securities being offered have not been registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

You May Also Be Interested In